Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

Table 1 Summary of patient baseline characteristics ^a

		GSK933776 dose
Demographic characteristics	Sex	1 mg/kg (n = 6)	3 mg/kg (n = 6)	6 mg/kg (n = 6)
Mean age (yr) (range)		69.0 (61 to 79)	68.3 (57 to 79)	66.0 (58 to 77)
Sex, n (%)	Female	2 (33)	5 (83)	3 (50)
	Male	4 (67)	1 (17)	3 (50)
Race, n (%)	Caucasian	6 (100)	6 (100)	6 (100)
Mean BMI kg/m² (range)		23.7 (20 to 26)	23.5 (21 to 28)	25.4 (22 to 27)
APOE ϵ4 status, n (%)	E2E3	0 (0)	0 (0)	0 (0)
	E3E3	1 (17)	0 (0)	0 (0)
	E3E4	3 (50)	2 (40)/1^b	3 (75)^c
	E4E4	2 (33)	3 (60)	1 (25)

^aBMI: Body mass index. ^bOne participant who entered the study and provided pharmacogenetics (PGx) consent and a sample in the 1 mg/kg dosing arm reentered the study in the 3 mg/kg dosing arm. The PGx consent and sample were obtained again unnecessarily for the 3 mg/kg dosing. The second PGx sample was subsequently destroyed to maintain consistency within the study by collecting and using only one sample per individual. ^cTwo participants who had entered the study and provided PGx consent and a sample in the 3 mg/kg dosing arm reentered the study in the 6 mg/kg dosing arm. The PGx consent and sample were not obtained again for these patients.

ISSN: 1758-9193